Safety – Page 99 – Communicable Diseases Research

COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies

다발성 경화증 환자의 COVID-19: 질병 수정 요법과의 연관성

Article

Published on 2021-03-012022-09-12
Journal: CNS drugs [Category] SARS, 진단,

Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity

COVID-19 환자를 위한 잠재적 치료제로서 하이드록시클로로퀸과 아지트로마이신의 조합: 안전성 프로파일, 약물 상호작용 및 독성 관리

Review

Published on 2021-03-012022-09-10
Journal: Microbial Drug Resistance [Category] SARS, 치료제,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 authorization Azithromycin caused clinical trial clinician Combination contagious contagious disease contributing to coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients disease drug Drug–drug interactions early treatment effective Efficacy Evidence Hydroxychloroquine identify Infection information Potential Prevent profile rationale reported respiratory Safe Safety severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 therapeutic strategy Toxicity treat Treatment
[DOI] 10.1089/mdr.2020.0232 PMC 바로가기 [Article Type] Review

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

Antiviral Agents

Published on 2021-03-012022-10-27
Journal: Antimicrobial Agents and Chemotherapy [Category] COVID-19,

[키워드] activity acute respiratory syndrome Administered administration adverse event agent Antiviral AUC C max clinically Concentration coronavirus COVID-19 declined decrease dose Dose escalation double-blind EIDD-1931 EIDD-2801 Electrocardiography evaluated exceeded expected first in human geometric healthy volunteers highest dose Human incidence influenza viruses Laboratory median time MERS-CoV Middle East Mild molnupiravir multiple dose multiple doses no decrease novel oral pandemic pharmacokinetics Phase 1 Placebo placebo-controlled study plasma plasma concentration Randomized Rash reached Registered reported respiratory syndrome coronavirus Ribonucleoside analog ribonucleoside analogue RNA viruses Safety SARS-CoV SARS-CoV-2 Serious Adverse Events single dose subject tested Tolerability vital signs
[DOI] 10.1128/AAC.02428-20 PMC 바로가기 [Article Type] Antiviral Agents

Salmonella Pullorum spiC mutant is a desirable LASV candidate with proper virulence, high immune protection and easy-to-use oral administration

살모넬라 풀로룸 spiC 돌연변이는 적절한 병원성, 높은 면역 보호 및 사용하기 쉬운 경구 투여를 갖춘 바람직한 LASV 후보입니다.

Article

Published on 2021-03-012024-08-21
Journal: Vaccine [Category] 살모넬라증,

[키워드] cellular immunity immune protection LASV-p Live attenuated Salmonella vaccine Safety Salmonella Pullorum
[DOI] 10.1016/j.vaccine.2021.01.059

First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021

Full Report

Published on 2021-02-262022-10-30
Journal: Morbidity and Mortality Weekly Report [Category] COVID-19,

[키워드] COVID-19 monitoring Month Safety United States
[DOI] 10.15585/mmwr.mm7008e3 PMC 바로가기 [Article Type] Full Report

Health Care Workers’ Reasons for Choosing Between Two Different COVID-19 Prophylaxis Trials in an Acute Pandemic Context: Single-Center Questionnaire Study

급성 전염병 상황에서 의료 종사자가 두 가지 다른 COVID-19 예방 실험 중에서 선택하는 이유: 단일 센터 설문 조사 연구

Original Paper

Published on 2021-02-252022-09-10
Journal: Journal of Medical Internet Research [Category] MERS, 임상,

[키워드] Adverse reaction Adverse reactions all subject all subjects asked benefit chose clinical trial clinical trials combination therapy contribute COVID-19 Efficacy emtricitabine evaluate expected followed by Health health benefits Health care Health care worker health care workers Hydroxychloroquine independent initial screening initiated majority melatonin motivation Nurse Nurses objective offered pandemic personnel physician Placebo pre-exposure professional practice Prophylaxis prophylaxis strategy Randomized reason respond Result Safety SARS-CoV-2 SARS-COV-2 infection screened selected significant difference significant differences tenofovir tenofovir disoproxil tested Treatment Trial trials Volunteer volunteers volunteers, web-based survey workplace safety
[DOI] 10.2196/23441 PMC 바로가기 [Article Type] Original Paper

Systemic Management of Pandemic Risks in Dental Practice: A Consolidated Framework for COVID-19 Control in Dentistry

Medicine

Published on 2021-02-242022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

Protocol for a patient-reported experience measures (PREMs) survey of patients discharged during the COVID-19 pandemic and their family caregivers

COVID-19 팬데믹 기간 동안 퇴원한 환자 및 가족 간병인에 대한 PREM(환자 보고 경험 측정) 조사 프로토콜

Article

Published on 2021-02-232022-09-11
Journal: BMJ Open [Category] 치료기술,

[키워드] Anderson Care clearance collected communication Complete COVID-19 COVID-19 hospitalisation COVID-19 pandemic discharged discharged home discharged patient discharged patients Effect ethical clearance Ethics ethics committee examined Families Family caregivers feeling Health health & Health services healthcare hospital hospitalised Human Human Research Ethics Committee include inferential statistics Intervention measure Nurse Nurses open Organisation of health services Pandemics participant Patient Perceived stress Perceived Stress Scale Perception physician public health quality in healthcare question questionnaire recommendation Research Ethics Risk perception Safety SARS-CoV-2 SARS-COV-2 infection scale second wave social determinant social determinants Stress Scale Support surgery the patient thematic analysis trajectory Trust undergo
[DOI] 10.1136/bmjopen-2020-047033 PMC 바로가기 [Article Type] Article

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

rAd26 및 rAd5 벡터 기반 이종 프라임-부스트 COVID-19 백신의 안전성 및 효능: 러시아의 무작위 대조 3상 시험 중간 분석

Clinical Trial

Published on 2021-02-202022-09-12
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, 진단,

[키워드] 95% CI Administered adverse event age Analysis assigned available data case report form Cellular immune response city clinical trials COVID-19 database death Department Direct dose double-blind Efficacy Efficacy and safety enrolment events excluded first dose full-length SARS-CoV-2 Gam-COVID-Vac glycoprotein Heterologous heterologous prime-boost hospital humoral IgG and IgM independent Infectious disease interim analysis intramuscularly Investment large cohort MOST participant Participants PCR-confirmed COVID-19 phase 3 trial Placebo placebo-controlled Primary outcome primary outcome analysis proportion protocol randomised randomised controlled Randomly receive receiving recombinant adenovirus Registered reported Russia Safety safety profile SARS-CoV-2 PCR second dose Serious Adverse Event Stratification the placebo group the vaccine Trial vaccination Vaccine vector were assessed
[DOI] 10.1016/S0140-6736(21)00234-8 PMC 바로가기 [Article Type] Clinical Trial

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials

아주부반응제 첨가 재조합 대상포진 백신은 50세 이상의 아시아 성인에서 효과적이고 안전하다: ZOE-50 및 ZOE-70 무작위 시험의 하위 집단 분석

Research Article

Published on 2021-02-192023-05-31
Journal: Human vaccines & immunotherapeutics [Category] Fulltext, 대상포진, 두창, 수두, 홍역,

[키워드] adjuvanted recombinant zoster vaccine Asian population Efficacy herpes zoster Postherpetic neuralgia Safety
[DOI] 10.1080/21645515.2020.1859321 PMC 바로가기 [Article Type] Research Article